Efficacy of immunotherapy with TG4040, peg-interferon, and ribavirin in a phase 2 study of patients with chronic HCV infection

Gastroenterology

Volumn 147, Issue 1, 2014, Pages

  Di Bisceglie, Adrian M ^a   Janczweska Kazek, Ewa ^b   Habersetzer, François ^c   Mazur, Wlodzimierz ^b   Stanciu, Carol ^d   Carreno, Vicente ^e   Tanasescu, Coman ^f   Flisiak, Robert ^g   Romero Gomez, Manuel ^h   Fich, Alexander ⁱ   Bataille, Vincent ^j   Toh, Myew Ling ^j   Hennequi, Marie ^j   Zerr, Patricia ^j   Honnet, Géraldine ^j   Inchauspé, Geneviève ^j   Agathon, Delphine ^j   Limacher, Jean Marc ^j   Wedemeyer, Heiner ^k  

^a Saint Louis University   (United States)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

^c HÔPITAL CIVIL   (France)

^d GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^e Foundation for the Study of Viral Hepatitis   (Spain)

^f V Babes National Institute of Pathology   (Romania)

^g MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^h HOSPITAL UNIVERSITARIO DE VALME   (Spain)

ⁱ BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^j TRANSGENE S A   (France)

^k HANNOVER MEDICAL SCHOOL   (Germany)

more..

Author keywords

ELISpot; Immune Response; SVR24; Vaccine

Indexed keywords

HEPATITIS C VACCINE; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; AGED; ALOPECIA; ANEMIA; ANTIVIRAL ACTIVITY; APLASTIC ANEMIA; ARTHRALGIA; ARTICLE; BODY MASS; CELLULITIS; CHRONIC DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; COUGHING; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; FATIGUE; FEMALE; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOTHERAPY; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INSOMNIA; LEUKOCYTOCLASTIC VASCULITIS; LEUKOPENIA; LOSS OF APPETITE; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VIRUS LOAD; VITAMIN D DEFICIENCY;

ELISPOT; IMMUNE RESPONSE; SVR24; VACCINE;

ADULT; AGED; ANTIBODIES, ANTI-IDIOTYPIC; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME; VIRAL VACCINES;

EID: 84902991292     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2014.03.007     Document Type: Article

References (34)

1. K. Mohd Hanafiah, J. Groeger, and A.D. Flaxman et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence Hepatology 57 2013 1333 1342
2. D. Lavanchy The global burden of hepatitis C Liver Int 29 2009 74 81
3. EASL Clinical Practice Guidelines Management of hepatitis C virus infection J Hepatol 55 2011 245 264
4. C. Sarrazin, C. Hezode, and S. Zeuzem et al. Antiviral strategies in hepatitis C virus infection J Hepatol 56 2012 S88 S100
5. G. Dusheiko, and H. Wedemeyer New protease inhibitors and direct-acting antivirals for hepatitis C: interferon's long goodbye Gut 61 2012 1647 1652
6. J. Torresi, D. Johnson, and H. Wedemeyer Progress in the development of preventive and therapeutic vaccines for hepatitis C virus J Hepatol 54 2011 1273 1285
7. P.P. Ip, H.W. Nijman, and J. Wilschut et al. Therapeutic vaccination against chronic hepatitis C virus infection Antiviral Res 96 2012 36 50
8. F. Habersetzer, G. Honnet, and C. Bain et al. A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C Gastroenterology 141 2011 890 899 e4
9. D.J. Sargent, V. Chan, and R.M. Goldberg A three-outcome design for phase II clinical trials Control Clin Trials 22 2001 117 125
10. J.G. McHutchison, E.J. Lawitz, and M.L. Shiffman et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection N Engl J Med 361 2009 580 593
11. G.L. Davis, J.B. Wong, and J.G. McHutchison et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C Hepatology 38 2003 645 652
12. T. Carlsson, O. Reichard, and G. Norkrans et al. Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response J Viral Hepat 12 2005 473 480
13. P. Ferenci, M.W. Fried, and M.L. Shiffman et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin J Hepatol 43 2005 425 433
14. F. Nevens, T. Roskams, and H. Van Vlierberghe et al. A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C Hepatology 38 2003 1092 1094
15. C.S. Klade, H. Wedemeyer, and T. Berg et al. Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41 Gastroenterology 134 2008 1385 1395
16. H. Wedemeyer, E. Schuller, and V. Schlaphoff et al. Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C Vaccine 27 2009 5142 5151
17. E.J. Gowans, S. Roberts, and K. Jones et al. A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals J Hepatol 53 2010 599 607
18. R. Dreicer, W.M. Stadler, and F.R. Ahmann et al. MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure Invest New Drugs 27 2009 379 386
19. F. Rahman, T. Heller, and Y. Sobao et al. Effects of antiviral therapy on the cellular immune response in acute hepatitis C Hepatology 40 2004 87 97
20. S.H. Park, S.R. Lee, and B.H. Hyun et al. Codelivery of PEG-IFN-alpha inhibits HCV DNA vaccine-induced T cell responses but not humoral responses in African green monkeys Vaccine 26 2008 3978 3983
21. E. Barnes, H.C. Gelderblom, and I. Humphreys et al. Cellular immune responses during high-dose interferon-alpha induction therapy for hepatitis C virus infection J Infect Dis 199 2009 819 828
22. J. Wiegand, M. Cornberg, and N. Aslan et al. Fate and function of hepatitis-C-virus-specific T-cells during peginterferon-alpha2b therapy for acute hepatitis C Antivir Ther 12 2007 303 316
23. J. Parrino, L.H. McCurdy, and B.D. Larkin et al. Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naive and vaccinia-immune individuals Vaccine 25 2007 1513 1525
24. C. Verheust, M. Goossens, and K. Pauwels et al. Biosafety aspects of modified vaccinia virus Ankara (MVA)-based vectors used for gene therapy or vaccination Vaccine 30 2012 2623 2632
25. PEGASYS® (peginterferon alfa-2a). Injection for subcutaneous use. US prescribing information. Revised September 2011 2011 Roche Pharmaceuticals Nutley, NJ
26. S. Nomura, T. Matsuzaki, and Y. Ozaki et al. Clinical significance of HLA-DRB1*0410 in Japanese patients with idiopathic thrombocytopenic purpura Blood 91 1998 3616 3622
27. P.J. Pockros, A. Duchini, and R. McMillan et al. Immune thrombocytopenic purpura in patients with chronic hepatitis C virus infection Am J Gastroenterol 97 2002 2040 2045
28. D. Buck, S. Cepok, and S. Hoffmann et al. Influence of the HLA-DRB1 genotype on antibody development to interferon beta in multiple sclerosis Arch Neurol 68 2011 480 487
29. M. Bax, J. van Heemst, and T.W. Huizinga et al. Genetics of rheumatoid arthritis: what have we learned? Immunogenetics 63 2011 459 466
30. P. Entz, B. Blaumeiser, and R.C. Betz et al. Investigation of the HLA-DRB1 locus in alopecia areata Eur J Dermatol 16 2006 363 367
31. A.M. Oksanen, K.E. Haimila, and H.I. Rautelin et al. Immunogenetic characteristics of patients with autoimmune gastritis World J Gastroenterol 16 2010 354 358
32. E. Gane Future perspectives: towards interferon-free regimens for HCV Antivir Ther 17 2012 1201 1210
33. L. Barrett, G. Shivasabesan, and C. Wang et al. Altered HCV specific T cell immunity very early in interferon free HCV daa therapy J Hepatol 58 2013 S1
34. Z. Moodie, L. Price, and C. Gouttefangeas et al. Response definition criteria for ELISPOT assays revisited Cancer Immunol Immunother 59 2010 1489 1501